Similar articles

• Commentary: NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma.

  Hambleton D. Hambleton D. BMJ. 2017 Oct 31;359:j5013. doi: 10.1136/bmj.j5013. BMJ. 2017. PMID: 29089330 No abstract available.
• Age-related macular degeneration: treatment at what cost?

  The Lancet. The Lancet. Lancet. 2018 Sep 29;392(10153):1090. doi: 10.1016/S0140-6736(18)32291-8. Lancet. 2018. PMID: 30303068 No abstract available.
• Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.

  Giberson M, Taylor V. Giberson M, et al. Can J Ophthalmol. 2015 Oct;50(5):393-4. doi: 10.1016/j.jcjo.2015.04.017. Can J Ophthalmol. 2015. PMID: 26455977 No abstract available.
• [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].

  Bro T. Bro T. Lakartidningen. 2017 Nov 28;114:ESF6. Lakartidningen. 2017. PMID: 29292948 Review. Swedish.
• Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.

  Vottonen P. Vottonen P. Acta Ophthalmol. 2018 Feb;96 Suppl A109:1-46. doi: 10.1111/aos.13706. Acta Ophthalmol. 2018. PMID: 29468838 Review. No abstract available.